XNCR News and Press, Xencor Inc. From 08/05/20

Xencor Inc (XNCR) Q2 2020 Results Conference Call August 04, 2020 4:30 PM ET Company Participants Charles Liles - Head of Investor Relations Bassil Dahiyat - President and Chief Executive Officer Allen Yeng - Chief Medical Officer John Desjarlais - Chief Scientific Officer ...

Image source: The Motley Fool. Xencor Inc   (NASDAQ: XNCR) Q2 2020 Earnings Call Aug 4, 2020 , 4:30 p.m. ET Operator Continue reading

Xencor (NASDAQ: XNCR ) : Q2 GAAP EPS of -$0.61 misses by $0.07 . More news on: Xencor, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

-- Management to Host Conference Call at 4:30 p.m. ET Today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter...

The FDA approval of MorphoSys' Monjuvi, in a treatment in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL), has triggered a $25 million milestone payment and royalty on net sales for Xencor (NASDAQ: XNCR ) , the co. announce...

-- Monjuvi is a new treatment in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) -- -- Tafasitamab-cxix was created at Xencor and is the second product with Xencor's XmAb ® technology to be approved by the FDA -- ...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will release second quarter 2020 financial results after the market closes on Tuesday, August 4, 2020...

Quick Take Pandion Therapeutics ( PAND ) intends to raise $93.5 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing treatments for serious gastrointestinal and liver immune diseases. PAND is in Phase 1 trials fo...

The second half of the year could provide some solid wins for investors in the cancer therapeutics market. In recent years, Wall Street has flocked to many of these biotechnology companies because of their potential to deliver cutting-edge treatments and generate long-term returns. As cancer ...

Atreca (NASDAQ: BCEL ) is  up 6%  premarket after entering into a collaboration and license agreement with Xencor (NASDAQ: XNCR ) to research, develop and commercialize T cell engaging bispecific antibodies as potential therapeutics in oncology. More news on: Atreca, Inc.,...